Loading...
•
Mar 31, 2021
Allovir Q1 2021 Earnings Report
AlloVir reported financial results for Q1 2021, highlighting progress in clinical trials and the appointment of Dr. Diana Brainard as CEO.
Key Takeaways
AlloVir reported a net loss of $30.9 million for the first quarter of 2021, with increased research and development and general and administrative expenses compared to the same period in 2020. The company's cash, cash equivalents, and marketable securities totaled $337.0 million as of March 31, 2021.
Dr. Diana Brainard was appointed as Chief Executive Officer, effective May 17, 2021.
The WHO approved posoleucel as the recommended international nonproprietary name for Viralym-M (ALVR105).
Phase 3 trial of Viralym-M for virus-associated HC in HSCT recipients is ongoing.
A POC clinical trial of ALVR106 in allogeneic and autologous HSCT recipients is expected to be initiated in the second half of 2021.
Forward Guidance
AlloVir is focused on advancing its pipeline of mid- and late-stage clinical trials and is on track to have initial data readouts from three clinical trials and initiate up to four more this year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...